<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7422">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927758</url>
  </required_header>
  <id_info>
    <org_study_id>CP-Sandoz-2009-PilotFP</org_study_id>
    <nct_id>NCT00927758</nct_id>
  </id_info>
  <brief_title>Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair</brief_title>
  <official_title>Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the post-dose changes in exhaled Nitric Oxide (eNO) following treatment with
      inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative
      for Asthma (GINA) guidelines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage Change From Baseline (for Each Treatment Cycle) in Exhaled Nitric Oxide (eNO)</measure>
    <time_frame>Baseline to Day 7 of each treatment cycle (total duration about 8 - 10 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage change in eNO was reported following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines. eNO was calculated 3 times every day in a treatment cycle for 7 days. The maximum value of all 3 collected value were collected for each seven days of the individual treatment cycle. Out of the maximum values, the minimum was taken and used for calculating the percentage change from baseline.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Sequence 1: Flu/Sal- 250mcg/50mcg -&gt;100mcg/50mcg-&gt;500mcg/50mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.
Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.
Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.
There were 14 days washout period between cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2: Flu/Sal- 500mcg/50mcg -&gt;250mcg/50mcg-&gt;100mcg/50mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.
Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.
Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.
There were 14 days washout period between cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3: Flu/Sal- 100mcg/50mcg -&gt;250mcg/50mcg-&gt;500mcg/50mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.
Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.
Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.
There were 14 days washout period between cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4: Flu/Sal- 250mcg/50mcg -&gt;500mcg/50mcg-&gt;100mcg/50mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.
Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.
Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.
There were 14 days washout period between cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5: Flu/Sal- 500mcg/50mcg -&gt;100mcg/50mcg-&gt;250mcg/50mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.
Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.
Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.
There were 14 days washout period between cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6: Flu/Sal- 100mcg/50mcg -&gt;500mcg/50mcg-&gt;250mcg/50mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.
Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.
Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.
There were 14 days washout period between cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg</intervention_name>
    <description>fluticasone propionate/salmeterol diskus</description>
    <arm_group_label>Sequence 1: Flu/Sal- 250mcg/50mcg -&gt;100mcg/50mcg-&gt;500mcg/50mcg</arm_group_label>
    <arm_group_label>Sequence 2: Flu/Sal- 500mcg/50mcg -&gt;250mcg/50mcg-&gt;100mcg/50mcg</arm_group_label>
    <arm_group_label>Sequence 3: Flu/Sal- 100mcg/50mcg -&gt;250mcg/50mcg-&gt;500mcg/50mcg</arm_group_label>
    <arm_group_label>Sequence 4: Flu/Sal- 250mcg/50mcg -&gt;500mcg/50mcg-&gt;100mcg/50mcg</arm_group_label>
    <arm_group_label>Sequence 5: Flu/Sal- 500mcg/50mcg -&gt;100mcg/50mcg-&gt;250mcg/50mcg</arm_group_label>
    <arm_group_label>Sequence 6: Flu/Sal- 100mcg/50mcg -&gt;500mcg/50mcg-&gt;250mcg/50mcg</arm_group_label>
    <other_name>Advair DISKUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must be able to speak, read, and understand English

          -  exhaled Nitrous Oxide levels must be greater than or equal to 60 ppb at screening and
             greater than or equal to 55 ppb at Visits 2, 9, and 16

          -  must have history of at least 6 months of chronic, but stable asthma

          -  except for the presence of asthma, subjects must be in general good health

        Exclusion Criteria:

          -  past or present history of experiencing allergic reaction to medications used in this
             study

          -  subjects must not be receiving ongoing regular treatment with inhaled corticosteroids

          -  subjects must not have ragweed allergy

          -  subjects must have no recent history of respiratory infections for at least 1 month
             prior to screening and until the end of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CompleWare</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>August 29, 2014</lastchanged_date>
  <firstreceived_date>June 23, 2009</firstreceived_date>
  <firstreceived_results_date>April 22, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Fluticasone, salmeterol drug combination</mesh_term>
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Salmeterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Actual screened patients was 105. However, 22 eligible patients were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1: Flu/Sal- 250mcg/50mcg -&gt;100mcg/50mcg-&gt;500mcg/50mcg</title>
          <description>Treatment cycle 1: Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for
7 days.
Treatement Cycle 2 : Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for
7 days.
Treatment Cycle 3: Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for
7 days.
There were 14 days washout period between cycles.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2: Flu/Sal- 500mcg/50mcg -&gt;250mcg/50mcg-&gt;100mcg/50mcg</title>
          <description>Treatment cycle 1: Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for
7 days.
Treatement Cycle 2 : Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for
7 days.
Treatment Cycle 3: Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for
7 days.
There were 14 days washout period between cycles.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3: Flu/Sal- 100mcg/50mcg -&gt;250mcg/50mcg-&gt;500mcg/50mcg</title>
          <description>Treatment cycle 1: Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for
7 days.
Treatement Cycle 2 : Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for
7 days.
Treatment Cycle 3: Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for
7 days.
There were 14 days washout period between cycles.</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4: Flu/Sal- 250mcg/50mcg -&gt;500mcg/50mcg-&gt;100mcg/50mcg</title>
          <description>Treatment cycle 1: Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for
7 days.
Treatement Cycle 2 : Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for
7 days.
Treatment Cycle 3: Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for
7 days.
There were 14 days washout period between cycles.</description>
        </group>
        <group group_id="P5">
          <title>Sequence 5: Flu/Sal- 500mcg/50mcg -&gt;100mcg/50mcg-&gt;250mcg/50mcg</title>
          <description>Treatment cycle 1: Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for
7 days.
Treatement Cycle 2 : Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for
7 days.
Treatment Cycle 3: Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for
7 days.
There were 14 days washout period between cycles.</description>
        </group>
        <group group_id="P6">
          <title>Sequence 6: Flu/Sal- 100mcg/50mcg -&gt;500mcg/50mcg-&gt;250mcg/50mcg</title>
          <description>Treatment cycle 1: Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for
7 days.
Treatement Cycle 2 : Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for
7 days.
Treatment Cycle 3: Patient randomized to Fluticasone
Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for
7 days.
There were 14 days washout period between cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Cycle 1 (Day 1 - Day 7)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4">&quot;Started &quot; indicates randomized as well as safety set.</participants>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent to Treat (ITT)</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Cycle 2 (Day 1 - Day 7)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Population (PP)</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet eNO criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Cycle 3 (Day 1 - Day 7)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Randomized Patients</title>
          <description>Baseline measured for all randomized (safety set) patients.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29.86" spread="10.40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change From Baseline (for Each Treatment Cycle) in Exhaled Nitric Oxide (eNO)</title>
        <description>Percentage change in eNO was reported following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines. eNO was calculated 3 times every day in a treatment cycle for 7 days. The maximum value of all 3 collected value were collected for each seven days of the individual treatment cycle. Out of the maximum values, the minimum was taken and used for calculating the percentage change from baseline.</description>
        <time_frame>Baseline to Day 7 of each treatment cycle (total duration about 8 - 10 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The per-protocol (PP) population was all subjects who completed the study with no major variances that would impair the analysis of the data</population>
        <group_list>
          <group group_id="O1">
            <title>Flu/Sal- 100mcg/50mcg</title>
            <description>All randomized patients Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Flu/Sal- 250mcg/50mcg</title>
            <description>All randomized patients Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Flu/Sal- 500mcg/50mcg</title>
            <description>All randomized patients Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage Change From Baseline (for Each Treatment Cycle) in Exhaled Nitric Oxide (eNO)</title>
            <description>Percentage change in eNO was reported following treatment with inhaled Advair in subjects with chronic but stable asthma as defined in Global Initiative for Asthma (GINA) guidelines. eNO was calculated 3 times every day in a treatment cycle for 7 days. The maximum value of all 3 collected value were collected for each seven days of the individual treatment cycle. Out of the maximum values, the minimum was taken and used for calculating the percentage change from baseline.</description>
            <units>Percentage change in eNO</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="36.65" spread="18.74"/>
                  <measurement group_id="O2" value="45.31" spread="16.46"/>
                  <measurement group_id="O3" value="54.58" spread="12.55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety set includes all subjects who received at least one dose of drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Flu/Sal- 100mcg/50mcg</title>
          <description>All randomized patients Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Flu/Sal- 250mcg/50mcg</title>
          <description>All randomized patients Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.</description>
        </group>
        <group group_id="E3">
          <title>Flu/Sal- 500mcg/50mcg</title>
          <description>All randomized patients Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dilated, Dry Eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Upper Respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Sandoz's agreements with its investigators may vary. However, Sandoz does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Sandoz</organization>
      <phone>609-627-8889</phone>
      <email>yaping.zhu@sandoz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
